Fig. 4. Effects of VEGF-A₁₆₄ antibody (ab, 1, 5 μg) injected intracisternally on formalin-induced nociceptive behavior. Intracisternal administration of 1 or 5 μg VEGF-A₁₆₄ antibody significantly decreased formalin-induced nociceptive behavior in the second phase as compared with the vehicle treatment. There were six animals in each group. *p<0.05, VEGF-A₁₆₄ antibody- vs. vehicle-treated group.

Oral Biol Res 2023;47:151~158 https://doi.org/10.21851/obr.47.04.202312.151

© Oral Biol Res